Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Fuji
Merck
Federal Trade Commission
Healthtrust
Queensland Health
US Army
Deloitte
Chinese Patent Office

Generated: April 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,673,838

« Back to Dashboard

Which drugs does patent 6,673,838 protect, and when does it expire?

Patent 6,673,838 protects PRISTIQ and is included in one NDA.

This patent has forty-three patent family members in thirty-one countries.
Summary for Patent: 6,673,838
Title: Succinate salt of O-desmethyl-venlafaxine
Abstract:A novel salt of O-desmethyl venlafaxine is provided, O-desmethylvenlafaxine succinate. Pharmaceutical compositions, dosage forms and methods of use are also provided.
Inventor(s): Hadfield; Anthony F. (Nanuet, NY), Shah; Syed M. (East Hanover, NJ), Winkley; Michael W. (Campbell Hall, NY), Sutherland; Karen W. (New City, NY), Provost; James A. (Waltham Chase, GB), Park; Aeri (West Lafayette, IN), Shipplett; Rex A. (Wolcott, IN), Russell; Brenton W. (West Lafayette, IN), Weber; Beat T. (Zofingen, CH)
Assignee: Wyeth (Madison, NJ)
Application Number:10/073,743
Patent Claim Types:
see list of patent claims
Compound; Composition; Dosage form; Formulation; Use;

Drugs Protected by US Patent 6,673,838

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Wyeth Pharms Inc PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-003 Aug 20, 2014 AB RX Yes No ➤ Sign Up ➤ Sign Up Y MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) ➤ Sign Up
Wyeth Pharms Inc PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-003 Aug 20, 2014 AB RX Yes No ➤ Sign Up ➤ Sign Up Y FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION ➤ Sign Up
Wyeth Pharms Inc PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-001 Feb 29, 2008 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) ➤ Sign Up
Wyeth Pharms Inc PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-001 Feb 29, 2008 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,673,838

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,026,508 Succinate salt of O-desmethyl-venlafaxine ➤ Sign Up
7,291,347 Succinate salt of O-desmethyl-venlafaxine ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Merck
Baxter
Teva
Colorcon
UBS
Argus Health
Federal Trade Commission
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.